We are requesting funds for a research career development program in Pediatric and Medical Oncology at the Fred Hutchinson Cancer Research Center and the University of Washington. The Career Development Program will interface with our Pediatric and Medical Oncology Research Training Programs at the Fred Hutchinson Cancer Research Center (FHCRC) and the Departments of Pediatrics and Medicine at the University of Washington (UW) with the goal of developing clinical investigators. It will support physicians who have completed three years of fellowship training in the pediatric or medical oncology training programs. Prior to entry into the program, fellows will have acquired clinical skills and basic laboratory tools of modern biology. Those most qualified and motivated to enter into investigative endeavors in clinical research will be selected. During their two to three years supported by the career development program, trainees will gain the tools and experience necessary to conduct clinical research, translate their findings to patients, and generate sufficient data to help establish independent research careers.
The aim of their projects will be to contribute new and useful information relevant to clinical oncology and to develop the clinical research capabilities of the trainees. Clinical research projects in the areas of bone marrow transplantation, immunology and immunotherapy, transplantation biology, normal and malignant hematopoiesis, human immunogenetics, neurooncology, molecular biology, and gene therapy, as well as other programs, will be used for training. Trainees will also gain experience in clinical protocol development, conduct, and evaluation, and will receive didactic training, in biostatistics, clinical trial design and biomedical research integrity. This program involves the laboratory and clinical research facilities of the Fred Hutchinson Cancer Research Center and the University of Washington, and the clinical facilities of the Seattle Cancer Care Alliance and the Division of Hematology-Oncology at the Children's Hospital and Regional Medical Center, the primary clinical pediatric service of the University of Washington.

Public Health Relevance

The aim of the Pediatric and Medical Oncology Career Development Program is to provide physicians with the tools and experience necessary to conduct clinical research, translate their findings to patients, and generate sufficient data to help establish independent research careers. Trainees will contribute new and useful information relevant to clinical oncology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA076930-15
Application #
8537826
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
1997-09-30
Project End
2014-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
15
Fiscal Year
2013
Total Cost
$596,700
Indirect Cost
$53,658
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Phipps, Colin; Gopal, Ajay K; Storer, Barry E et al. (2015) Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity. Leuk Lymphoma 56:92-6
Hsieh, Y T; Gang, E J; Shishido, S N et al. (2014) Effects of the small-molecule inhibitor of integrin ?4, TBC3486, on pre-B-ALL cells. Leukemia 28:2101-4
Dahlberg, A; Brashem-Stein, C; Delaney, C et al. (2014) Enhanced generation of cord blood hematopoietic stem and progenitor cells by culture with StemRegenin1 and Delta1(Ext-IgG.). Leukemia 28:2097-101
Matesan, Manuela; Rajendran, Joseph; Press, Oliver W et al. (2014) 90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution. Nucl Med Commun 35:1132-42
Ostronoff, Fabiana; Othus, Megan; Gerbing, Robert B et al. (2014) NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood 124:2400-7
Rezvani, Andrew R; McCune, Jeannine S; Storer, Barry E et al. (2013) Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes. Biol Blood Marrow Transplant 19:1033-9
Pollard, Jessica A; Alonzo, Todd A; Loken, Michael et al. (2012) Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood 119:3705-11
Yeh, Rosa F; Pawlikowski, Matthew A; Blough, David K et al. (2012) Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 18:265-72
Rezvani, Andrew R; Storer, Barry E; Storb, Rainer F et al. (2011) Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 17:1594-601
Palanca-Wessels, Maria C; Convertine, Anthony J; Cutler-Strom, Richelle et al. (2011) Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells. Mol Ther 19:1529-37

Showing the most recent 10 out of 36 publications